DOP2022000156A - Célula cho que expresa heterodímeros il–15 - Google Patents

Célula cho que expresa heterodímeros il–15

Info

Publication number
DOP2022000156A
DOP2022000156A DO2022000156A DO2022000156A DOP2022000156A DO P2022000156 A DOP2022000156 A DO P2022000156A DO 2022000156 A DO2022000156 A DO 2022000156A DO 2022000156 A DO2022000156 A DO 2022000156A DO P2022000156 A DOP2022000156 A DO P2022000156A
Authority
DO
Dominican Republic
Prior art keywords
cho cell
cell expressing
heterodimer
il15ra
treatment
Prior art date
Application number
DO2022000156A
Other languages
English (en)
Inventor
Gabriel Richard
Jostock Thomas
JOZEFCZUK Justyna
Ulrich LOHRIG Urs
Aurélien Pons Alexander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DOP2022000156A publication Critical patent/DOP2022000156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al heterodímero de IL–15/IL–15Ra 5 producido en una línea celular CHO, y método de producción del heterodímero y método de tratamiento utilizando el heterodímero.
DO2022000156A 2020-02-05 2022-08-03 Célula cho que expresa heterodímeros il–15 DOP2022000156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05
PCT/IB2021/050730 WO2021156720A1 (en) 2020-02-05 2021-01-29 Cho cell expressing il-15 heterodimers

Publications (1)

Publication Number Publication Date
DOP2022000156A true DOP2022000156A (es) 2022-10-16

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000156A DOP2022000156A (es) 2020-02-05 2022-08-03 Célula cho que expresa heterodímeros il–15

Country Status (21)

Country Link
US (1) US20210244821A1 (es)
EP (1) EP4100425A1 (es)
JP (2) JP2022522566A (es)
KR (1) KR20220137651A (es)
CN (1) CN115023436A (es)
AR (1) AR121261A1 (es)
AU (1) AU2021215893A1 (es)
BR (1) BR112022014493A2 (es)
CA (1) CA3168469A1 (es)
CL (2) CL2022002094A1 (es)
CO (1) CO2022010860A2 (es)
CR (1) CR20220367A (es)
DO (1) DOP2022000156A (es)
EC (1) ECSP22060286A (es)
IL (1) IL295278A (es)
JO (1) JOP20220174A1 (es)
MX (1) MX2022009611A (es)
PE (1) PE20221509A1 (es)
TW (1) TW202142558A (es)
UY (1) UY39062A (es)
WO (1) WO2021156720A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021372660A1 (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
IL302321A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
WO2024097918A1 (en) 2022-11-04 2024-05-10 Novartis Ag Nkg2d fusion protein cancer therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
US8021668B2 (en) 2005-12-12 2011-09-20 Immune Disease Institute, Inc. Integrin alpha L I domain mutants with increased binding affinity
CN102796743B (zh) * 2006-01-13 2015-11-18 美国政府健康及人类服务部国立卫生研究院 用于在哺乳动物细胞中表达的密码子优化的IL-15和IL-15Rα基因
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
ES2518393T3 (es) * 2007-05-11 2014-11-05 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
US8459743B2 (en) 2008-08-22 2013-06-11 Magna Seating Inc. Disc recliner with reduced backlash
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
JP6359019B2 (ja) * 2012-10-24 2018-07-18 ノバルティス アーゲー ＩＬ−１５Ｒα型、ＩＬ−１５Ｒα型を発現する細胞、ならびにＩＬ−１５ＲαおよびＩＬ−１５／ＩＬ−１５Ｒα複合体の治療上の使用
KR102307278B1 (ko) 2014-04-29 2021-09-30 노파르티스 아게 신규 척추동물 세포 및 관심 폴리펩티드의 재조합적 발현 방법
RU2711979C2 (ru) * 2014-12-19 2020-01-23 Цзянсу Хэнжуй Медсин Ко., Лтд. Белковый комплекс интерлейкина 15 и его применение
CA3032669A1 (en) * 2016-08-01 2018-02-08 William Jia Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
KR20190091264A (ko) * 2016-10-21 2019-08-05 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
CN110177568A (zh) * 2017-01-20 2019-08-27 诺华股份有限公司 用于治疗癌症的组合疗法
EP3746104A1 (en) * 2018-02-02 2020-12-09 Novartis AG Combination of sting agonist and il-15/il15-ra for the treatment of cancer
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物

Also Published As

Publication number Publication date
AU2021215893A1 (en) 2022-08-25
UY39062A (es) 2021-09-30
BR112022014493A2 (pt) 2022-09-20
KR20220137651A (ko) 2022-10-12
CR20220367A (es) 2022-08-30
CL2022002094A1 (es) 2023-03-10
CA3168469A1 (en) 2021-08-12
CO2022010860A2 (es) 2022-08-19
EP4100425A1 (en) 2022-12-14
CL2023002447A1 (es) 2024-03-15
JOP20220174A1 (ar) 2023-01-30
ECSP22060286A (es) 2022-09-30
PE20221509A1 (es) 2022-10-04
MX2022009611A (es) 2022-11-07
TW202142558A (zh) 2021-11-16
US20210244821A1 (en) 2021-08-12
JP2023145622A (ja) 2023-10-11
AR121261A1 (es) 2022-05-04
JP2022522566A (ja) 2022-04-20
WO2021156720A1 (en) 2021-08-12
CN115023436A (zh) 2022-09-06
IL295278A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
DOP2022000156A (es) Célula cho que expresa heterodímeros il–15
CO2018001450A2 (es) Obtención de fosfatasas alcalinas
BR112015019997A2 (pt) Métodos de sacarificar e fermentar um material celulósico
CL2017000752A1 (es) Procedimiento para producir biomasa que tiene un alto contenido de exopolisacáridos
AR072376A1 (es) Induccion de floculacion en organismos fotosinteticos tales como algas
IN2015DN02458A (es)
CR11194A (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
CO2021002704A2 (es) Método de producción de precursores neuronales entéricos
Garfinkel et al. What is ethnomethodology
DE602005026185D1 (de) Verfahren zum herstellen eines hörgeräts auf der basis von personalitätsprofilen
MX2020003668A (es) Tratamiento de la enfermedad mediada por cml.
BR112022010694A2 (pt) Método e kit para crescimento celular
BR112016009619A2 (pt) métodos para sacarificar um material celulósico e para produzir um produto de fermentação a partir de material celulósico
SA518392108B1 (ar) الأكسدة الكهربائية عند ضغوط مرتفعة
PH12021550347A1 (en) MICROORGANISM FOR PRODUCING L-AMINO ACID WITH ENHANCED ACTIVITY OF a-GLUCOSIDASE AND METHOD FOR PRODUCING L-AMINO ACID USING THE SAME
EA201692347A1 (ru) Способ гидролиза лигноцеллюлозного материала, где гидролизат используют для получения микробной гидролазы
AR095765A1 (es) Aditivos viscosificantes con arcilla beneficiada
PL405046A1 (pl) Genetycznie kodowany oparty na FRET biosensor aktywności MMP-9 i jego zastosowanie
FR3093732B1 (fr) Procédé de production d’une biomasse cellulaire microbienne ayant des propriétés de floculant
BR112023018344A2 (pt) Composições de cimento, e métodos das mesmas
CL2021003248A1 (es) Materiales de compostaje y métodos de producción de los mismos.
AR121881A1 (es) Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos
WO2019078523A3 (en) Collagen membrane with excellent physical properties and manufacturing method thereof
PE20211097A1 (es) Cultivar de stevia aneuploide 'ap-1'
Nalin Evaluation and recommendation on Inner Mongolian FDI to Mongolia in the framework of “One Belt, One Road”